After years of preparation, Eli Lilly is on the brink of launching ... head of connected care for Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look forward to continually ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron ... after shrugging off medical care for the conditions, a new study says.

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Eli Lilly is partnering ... GLP-1 weight loss and diabetes medications Mounjaro and Zepbound. Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing ...

Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market. In premarket trading ...

Eli Lilly's stock boomed ... of the trial were released. Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.